Unlocking the Reverse Targeting Mechanisms of Cannabidiol: Unveiling New Therapeutic Avenues

被引:0
|
作者
Zeng, Wen [1 ,2 ]
Wang, Yifei [1 ]
Gao, Rui [1 ]
Wen, Hongliang [1 ,2 ]
Yu, Mingjia [1 ]
机构
[1] Beijing Inst Technol, Sch Chem & Chem Engn, Beijing 100081, Peoples R China
[2] Beijing Inst Technol, Yangtze Delta Reg Acad, Key Lab Med Mol Sci & Pharmaceut Engn, Jiaxing 314019, Peoples R China
基金
中国国家自然科学基金;
关键词
MOLECULAR-DYNAMICS SIMULATION; PROTEIN; INTEGRATION; GENERATION; PREDICTION; MODEL;
D O I
10.1021/acs.jmedchem.4c01353
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cannabidiol (CBD) and Delta 9-tetrahydrocannabinol (THC), the main components of Cannabis sativa plants, have attracted a significant amount of attention due to their biological activities. This study identified GPR18 as the target of partial agonist CBD activating the p42/p44 MAPK pathway leading to migration of endometrial epithelial cells. Induced fit docking (IFD) showed that the affinity of THC for GPR18 is higher than that of CBD, and molecular dynamics (MD) simulations showed that CBD-GPR18 complexes at 130/200 ns might have stable conformations, potentially activating GPR18 by changing the distances of key residues in its active pocket. In contrast, THC maintains "metastable" conformations, generating a "shrinking space" leading to full agonism of THC by adding mechanical constraints in GPR18's active pocket. Steered molecular dynamics (SMD) revealed GPR18's active pocket was influenced more by CBD's partial agonism compared with THC. This combined IFD-MD-SMD method may be used to explain the mechanism of activation of partial or full agonists of GPR18.
引用
收藏
页码:14574 / 14585
页数:12
相关论文
共 50 条
  • [31] New avenues for NASH therapy by targeting ACC
    Bian, Huijie
    Liu, Ye-Mao
    Chen, Zhi-Nan
    CELL METABOLISM, 2022, 34 (02) : 191 - 193
  • [32] Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy
    Singh, Vipin
    Nandi, Sandhik
    Ghosh, Aritra
    Adhikary, Santanu
    Mukherjee, Shravanti
    Roy, Siddhartha
    Das, Chandrima
    CANCER AND METASTASIS REVIEWS, 2024, 43 (01) : 175 - 195
  • [33] Unlocking the potential of alkalizing bacteria in cadmium remediation: Unveiling mechanisms and efficacy
    Wang, Tong
    Zhang, Jiawen
    Guan, Haoran
    Xu, Jianming
    Liu, Xingmei
    ENVIRONMENTAL TECHNOLOGY & INNOVATION, 2024, 36
  • [34] New therapeutic avenues for Duchenne muscular dystrophy
    Kirschner, Janbernd
    LANCET NEUROLOGY, 2024, 23 (04): : 330 - 331
  • [35] Diabetes and vascular disease: New therapeutic avenues
    Del Prato, Stefano
    VASCULAR PHARMACOLOGY, 2024, 154
  • [36] Cancer "Clock" Opens New Therapeutic Avenues
    Dolgin, Elie
    CANCER DISCOVERY, 2017, 7 (12) : 1358 - 1358
  • [37] Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets
    Dey, Asmita Deka
    Mannan, Ashi
    Dhiman, Sonia
    Singh, Thakur Gurjeet
    PSYCHOPHARMACOLOGY, 2024, 241 (08) : 1491 - 1516
  • [38] Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues
    Esther H. Bae
    Mark K. Greenwald
    Ann G. Schwartz
    Neurotherapeutics, 2021, 18 : 2384 - 2396
  • [39] Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
    Samudra, Niyatee
    Lane-Donovan, Courtney
    VandeVrede, Lawren
    Boxer, Adam L.
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (12):
  • [40] Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues
    Bae, Esther H.
    Greenwald, Mark K.
    Schwartz, Ann G.
    NEUROTHERAPEUTICS, 2021, 18 (04) : 2384 - 2396